Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 971-975

  Pea, Federico ^a   Brollo, Loris ^a   Viale, Pierluigi ^a   Pavan, Federica ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Hypoalbuminaemia; Loading dose; Renal function; TDM; Teicoplanin

Indexed keywords

AMIKACIN; CYCLOSPORIN; NETILMICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CREATININE; CRITICAL CARE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TEICOPLANIN;

EID: 0037395975     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg147     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. (2002). Guidelines for the prevention of intravascular catheter-related infections. Morbidity and Mortality Weekly Report 51, 1-29.
2. Centers for Disease Control and Prevention. (1999). National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. American Journal of Infection Control 27, 520-32.
3. Diekema, D. J., Pfaller, M. A., Schmitz, F. J., Smayevsky, J., Bell, J., Jones, R. N. et al. (2001). Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases 32, S114-32.
4. Wood, M. J. (1999). Chemotherapy for Gram-positive nosocomial sepsis. Journal of Chemotherapy 11, 446-52.
5. Rodriguez-Bano, J. (2002). Selection of empiric therapy in patients with catheter-related infections. Clinical Microbiology and Infection 8, 275-81.
6. Pea, F., Porreca, L., Baraldo, M. & Furlanut, M. (2000). High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. Journal of Antimicrobial Chemotherapy 45, 329-35.
7. Leader, W. G., Chandler, M. H. & Castiglia, M. (1995). Pharmacokinetic optimisation of vancomycin therapy. Clinical Pharmacokinetics 28, 327-42.
8. MacGowan, A. P. (1998). Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Therapeutic Drug Monitoring 20, 473-7.
9. MacGowan, A. P., McMullin, C. M., White, L. O., Reeves, D. S., Davis, E. & Speller, D. C. (1992). Serum monitoring of teicoplanin. Journal of Antimicrobial Chemotherapy 30, 399-402.
10. Begg, E. J., Barclay, M. L. & Kirkpatrick, C. M. (2001). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology 52, 35S-43S.
11. Wilson, A. P. (2000). Clinical pharmacokinetics of teicoplanin. Clinical Pharmacokinetics 39, 167-83.
12. Schaison, G., Graninger, W. & Bouza, E. (2000). Teicoplanin in the treatment of serious infection. Journal of Chemotherapy 12, 26-33.
13. Cockcroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
14. Awni, W. M., St Peter, W. L., Guay, D. R., Kenny, M. T. & Matzke, G. R. (1991). Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay, and high-performance liquid chromatographic assay. Therapeutic Drug Monitoring 13, 511-7.
15. Cox, H., Whitby, M., Nimmo, G. & Williams, G. (1993). Evaluation of a novel fluorescence polarization immunoassay for teicoplanin. Antimicrobial Agents and Chemotherapy 37, 1924-6.
16. Schentag, J. J. (2001). Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Critical Care Medicine 29, N100-7.
17. Weinbren, M. & Struthers, K. (2002). Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy. Journal of Antimicrobial Chemotherapy 50, 306-7.
18. Harding, I., MacGowan, A. P., White, L. O., Darley, E. S. & Reed, V. (2000). Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. Journal of Antimicrobial Chemotherapy 45, 835-41.
19. Wilson, A. P., Gruneberg, R. N. & Neu, H. (1993). Dosage recommendations for teicoplanin. Journal of Antimicrobial Chemotherapy 32, 792-6.
20. Dykhuizen, R. S., Harvey, G., Stephenson, N., Nathwani, D. & Gould, I. M. (1995). Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrobial Agents and Chemotherapy 39, 1842-7.
21. Pea, F., Furlanut, M., Poz, D. & Baraldo, M. (1999). Pharmacokinetic profile of two different administration schemes of teicoplanin. Single 400 mg intravenous dose vs double-refracted 200 mg intramuscular doses in healthy volunteers. Clinical Drug Investigation 18, 47-55.
22. Pachon, J., Prados, D., Palomino, J., Cantos, A., Cisneros, J. M. & Vaquero, F. (1996). Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 37, 197-200.
23. Wood, M. J. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
24. Wood, M. J. (2000). Comparative safety of teicoplanin and vancomycin. Journal of Chemotherapy 12, 21-5.
25. Wada, D. R., Drover, D. R. & Lemmens, H. J. (1998). Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clinical Pharmacokinetics 35, 1-7.
26. Pea, F., Brollo, L., Lugano, M., Dal Pos, L. & Furlanut, M. (2001). Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Therapeutic Drug Monitoring 23, 587-8.
27. Pea, F. & Furlanut, M. (2001). Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clinical Pharmacokinetics 40, 833-68.